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Background: HIV co-infection exacerbates hepatitis C disease, increasing the risk of cirrhosis and hepatitis C-related
mortality. Combination antiretroviral therapy (cART) is the current standard treatment for co-infected individuals, but
the impact of cART and antiretroviral (ARV) monotherapy on liver disease in this population is unclear. We aimed to
assess the effect of cART and ARV monotherapy on liver disease progression and liver-related mortality in
individuals co-infected with HIV and chronic hepatitis C.
Methods: A systematic review with meta-analyses was conducted. MEDLINE and EMBASE bibliographic databases
were searched up to September 2015. Study quality was assessed using a modified Newcastle-Ottawa scale. Results
were synthesised narratively and by meta-analysis.
Results: Fourteen observational studies were included. In analyses that adjusted for potential confounders, risk of
liver-related mortality was significantly lower in patients receiving cART (hazard ratio/odds ratio 0.31, 95 % CI 0.14 to
0.70). Results were similar in unadjusted analyses (relative risk 0.40, 95 % CI 0.29 to 0.55). For outcomes where meta-
analysis could not be performed, results were less consistent. Some studies found cART was associated with lower
incidence of, or slower progression of liver disease, fibrosis and cirrhosis, while others showed no evidence of benefit.
We found no evidence of liver-related harm from cART or ARV monotherapy compared with no HIV therapy.
Conclusions: cART was associated with significantly lower liver-related mortality in patients co-infected with HIV and
HCV. Evidence of a positive association between cART and/or ARV monotherapy and liver-disease progression was less
clear, but there was no evidence to suggest that the absence of antiretroviral therapy was preferable.
Keywords: Systematic review, Meta-analysis, Anti-retroviral agents, Hepatitis C, HIV
Abbreviations: ARV, Antiretroviral therapy; cART, Combination antiretroviral therapy; HCV, Hepatitis C virus; HR, Hazard
ratio; IDU, Injection drug use; MD, Mean difference; OR, Odds ratio; RR, Relative riskBackground
Hepatitis C is an infectious liver disease caused by the
hepatitis C virus (HCV). Hepatitis C infections occur if
the virus is able to enter the blood stream and reach the
liver. Co-infection with hepatitis C virus (HCV) and hu-
man immunodeficiency virus (HIV) is common due to
similar modes of transmission. There are an estimated 7* Correspondence: amanda.sowden@york.ac.uk
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HIV [1]. Chronic HCV infection affects approximately
6.2 % of HIV positive individuals, with greater rates in
intravenous drug users [2]. HIV co-infection exacerbates
HCV disease, increasing the risk of cirrhosis and HCV-
related mortality [3].
In high-income countries, the widespread use of
monotherapy with an antiretroviral drug (or ARV mono-
therapy) in the late 80s, followed by combination anti-
retroviral therapy (cART) since 1996 has resulted in
HIV-infected patients living longer, and chronic HCVle is distributed under the terms of the Creative Commons Attribution 4.0
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death, after AIDS-related complications, among HIV-
infected individuals in areas where cART is available [1].
The effect of cART on the clinical course of HCV infec-
tion is not clear. It has been suggested that the HIV viral
suppression [4] and immune reconstitution possible with
cART are critical factors that slow down the rate of
HCV fibrosis progression [5]. However, some studies
have reported that cART may adversely affect hepatitis
C-related outcomes by increasing HCV viral load, liver
toxicity and fibrosis progression [6–8].
Today, most individuals infected with HCV in high-
income countries acquire the virus through unsterile drug
injecting practices. However, before the introduction of ef-
fective blood donor screening, individuals became infected
through blood transfusion or therapy with medical prod-
ucts manufactured from donated human blood. It is esti-
mated that blood transfusion resulted in approximately
23,500 HCV transmissions during the 1970s and 1980s in
England, [9] and around 28,000 in the UK, [10] before an
effective blood donor screening test was introduced in the
UK in 1991. More than 4,600 patients with bleeding
disorders were also infected via treatment with HCV-
contaminated plasma products. Since 2004, those surviv-
ing patients who acquired chronic HCV infection through
NHS contaminated blood or blood products before donor
screening tests or virus inactivation methods were avail-
able have received financial help via a UK wide ex-gratia
scheme established by the Department of Health [11].
We report the findings from a systematic review that
was commissioned by the Department of Health, England
[12]. cART is the current standard treatment for this pa-
tient group but its impact on liver disease progression and
liver related mortality is unclear. Evidence of harm associ-
ated with cART and/or ARV monotherapy may have im-
plications for compensation policies for people who
acquired HCV through contaminated blood products
prior to 1991. The findings from an earlier review examin-
ing the association between cART and ARV monotherapy
and liver disease outcomes were inconclusive [13]. Since
publication of the review in 2007 new primary studies
have become available and an up-to-date review of the
available evidence is needed.
Methods
We followed the general principles recommended in
Centre for Reviews and Dissemination (CRD) Guidance
for Undertaking Reviews in Health Care, [14] and the
reporting guidance of the PRISMA and MOOSE state-
ments [15, 16].
Search strategy
MEDLINE and EMBASE electronic databases were
searched up to September 2015 for studies published inEnglish. We applied no date restrictions or study design
filters. Search terms included “hepatitis C”, “HIV”, “anti-
retroviral therapy”, and “liver disease”. The reference lists
of relevant published reviews were checked for additional
studies [13, 17–19]. A full search strategy is reported in
the Additional file 1.
Study selection
Studies evaluating the effect of cART and/or ARV
monotherapy in individuals co-infected with HIV and
HCV were eligible for inclusion. Studies had to include a
comparison group of participants who did not receive
the intervention. Studies that measured treatment ex-
posure and outcome at the same point in time were ex-
cluded because they were not considered suitable for
measuring disease progression.
The two outcomes of interest were liver-related mortal-
ity and liver disease progression, and the latter includes
progression to/of fibrosis and cirrhosis; decompensated
liver disease; end-stage liver disease; and hepatocellular
carcinoma. Outcomes had to be measured using liver bi-
opsy or a validated non-invasive method. Studies examin-
ing HCV viral load or transaminase/aminotransferase only
were excluded. Data had to be presented as, or allow cal-
culation of, relative risks (RR), odds ratios (OR), hazard ra-
tios (HR), or mean differences (MD).
Titles and abstracts were screened by a single reviewer,
and full papers were assessed by two reviewers independ-
ently, with disagreements resolved through discussion.
Data extraction and risk of bias
Relevant study details and patient characteristics (e.g., age,
sex, baseline liver disease severity, mode of HCV/HIV in-
fection; HIV/HCV treatment regimens and history; con-
comitant treatments) and outcomes were extracted into
standardised forms. Where outcomes were reported with
different levels of adjustment (e.g., adjusting for age and
sex only versus age, sex and time-dependent covariates),
data with the greatest number of adjustments were pre-
ferred. Risk of bias was evaluated using a modified version
of the Newcastle-Ottawa quality assessment tool [20].
Three main domains were considered: participant selec-
tion, confounding, and outcome measurement. Further de-
tails are reported in the Supporting Information. Data were
extracted by a single reviewer and checked by a second,
with disagreements resolved through discussion. Where
relevant, study authors were contacted for missing data.
Synthesis
Results for liver-related mortality and liver disease pro-
gression were pooled in a meta-analysis if at least two
studies reported that outcome, and if data were reported
consistently enough for analysis to be feasible. Otherwise,
results were synthesised narratively. Where meta-analyses
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random-effects DerSimonian-Laird meta-analyses [21].
Heterogeneity was assessed through visual inspection of
forest plots and using I2 [22]. When pooling adjusted odds,
hazard or risk ratios these were assumed to be equivalent
regardless of the specific statistic reported or which covari-
ates were used in adjusted models. Adjusted and un-
adjusted ratios were pooled using the inverse variance
method. Meta-analyses were conducted using R software.
Where participants from several studies were recruited
from the same cohorts and significant overlap was sus-
pected, data from only one study with the most reliable
reporting were included in the main analyses. The im-
pact of suspected overlap in participants across studies
was explored in sensitivity analyses, as was the use of
composite outcomes (one study reported end-stage liver
disease, hepatocellular carcinoma or death only as a
composite outcome [23]).
Where possible, pre-planned subgroup analyses in-
cluding only studies with a large proportion of patients
with haemophilia were conducted. Meta-regression ana-
lyses or other subgroup analyses were considered in-
appropriate due to the small number of studies.
Results
The bibliographic searches yielded a total of 1,943 unique
records. From these, 96 studies of potential relevance wereRecords identified through database searching to
2,250
Records after duplicates were removed
1,943
Records screened by 
author and title
1,943
Full-text articles assessed for eligibility
96
Studies included in the review
14
Included in meta -analysis: 6
Included in narrative synthesis only: 
Fig. 1 Flow of studiesidentified and 14 studies met our inclusion criteria (see
Fig. 1 for further details).
Risk of bias
As would be expected in observational studies, risk of
confounding of results due to unmeasured factors was the
most frequent quality concern in the included studies, with
ten studies classed at moderate or high risk of bias. Risk of
bias associated with participant selection was considered
unclear due to limited reporting in five studies, and low in
nine studies (where the study sample was considered
broadly representative of the population of interest, and as-
sessment of HIV/HCV and outcome at baseline were con-
sidered appropriate). The risk of bias associated with
outcome measurement was considered mostly low, as ten
studies measured and reported their outcomes using appro-
priate methods. Further details about quality criteria and
judgments are reported in Table 1 and Additional file 2.
Study characteristics
Most studies were carried out in Europe, with six from
Spain, two from Italy and one in each of France,
Germany and Austria. Three studies were carried out in
the USA. Study dates ranged from 1970 to 2011 and six
studies were conducted across the pre-post cART era
(before and after 1996) [23–28]. Seven studies followed
patients prospectively in time [23, 27, 29–33] and the September 2015 
 
Records excluded 
1,847
Full-text articles excluded: 
82
Reasons for exclusion
Ineligible population (no 
separate data on co-
infected patients) : 1
No relevant data on 
intervention: 2
No comparator group: 26
No eligible liver -disease 
related  outcome: 30
No eligible design (e.g. 
cross-sectional): 23
8
Table 1 Risk of bias
Selection
bias
Confounding
bias
Outcome
measurement
bias
Bruno (2007) [34] Low Moderate Low
Giron-Gonzalez (2007) [29] Unclear Moderate Low
Limketkai (2012) [23] Low Low Low
Macias (2006) [25] Low Moderate Low
Macias (2009) [24] Low Low Unclear
Mariné-Barjoan (2004) [35] Low High Low
Mehta (2005) [30] Unclear High High
Merchante (2006) [31] Unclear High Low
Pineda (2009) [32] Low Moderate Low
Qurishi (2003) [26] Unclear Low Low
Ragni (2009) [27] Low Low Unclear
Reiberger (2010) [36] Low High Low
Sanmartin (2014) [33] Low High High
Schiavini (2006) [28] Unclear High Low
Total risk of bias 9 low 4 low 10 low
0 high 6 high 2 high
5 unclear 4 moderate 2 unclear
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[24–26, 28, 34–36].
Many participants were current or past injection drug
users (IDU), with eight studies having IDU rates of 72 %
or above. One study focused on patients with haemo-
philia exclusively [27], and another reported that 81 % of
patients had the condition [26]. The other studies failed
to report the number of patients with haemophilia. Base-
line liver damage severity varied across the studies: ten
studies included no or few patients with cirrhosis
[23–28, 30, 33, 35, 36]; four studies included only patients
with compensated cirrhosis at baseline [29, 31, 32, 34].
Where reported, cART regimens were primarily based on
protease inhibitors and non-nucleoside reverse transcript-
ase inhibitors. Further study characteristics are presented
in Table 2.
Seven studies reported data on liver-related mortality,
[23, 26, 27, 29, 31, 32, 34] and ten studies reported on
liver disease progression [24, 25, 27–30, 32, 33, 35, 36].
Three studies reported separate data on both outcomes
[27, 29, 32].
Liver-related mortality
Findings from six of the seven studies on liver-related
mortality were combined in meta-analyses [23, 26, 27,
29, 32, 34]. Of those, four studies presented analyses ad-
justed for potential confounding factors [23, 26, 29, 32].
Figure 2 presents a forest plot of the results from these
four studies. cART use was associated with a substantialreduction in liver-related mortality, with a hazard/odds
around one-third of that in untreated patients (HR/OR
0.31, 95 % CI 0.14 to 0.70). Heterogeneity was high
(I2 = 95 %), likely to be due to the discordant result
between two studies [26, 32]. One showed a much
larger benefit; most participants in this study had
haemophilia, whereas in the other studies a large ma-
jority of patients had a history of IDU.
All six studies included in the meta-analysis presented
numbers of patients with and without liver-related mor-
tality from which unadjusted relative risks could be cal-
culated. Figure 3 presents a forest plot of the results.
cART is associated with a statistically significant lower
risk of liver-related mortality (RR 0.40, 95 % CI 0.29 to
0.55). Moderate heterogeneity was found (I2 = 24 %).
Subgroup analysis
Figure 4 presents the forest plot for the two studies
which included primarily patients with haemophilia.
cART is associated with a reduced risk of liver related
mortality (RR 0.28, 95 % CI 0.09 to 0.83), but there is
too little data to accurately estimate the effect, or to de-
termine if the effect differs from patients with a history
of IDU.
Sensitivity analyses
The number of liver-related deaths per group was not
reported in one [23] of the two studies, but it appears
that at least 63 % of the events reported across the two
study groups were liver-related deaths. Removing this
study from the analyses had only a limited effect on the
pooled estimates (RR 0.35, 95 % CI 0.21 to 0.57).
Results from one study [31] were not included in the
main analyses to avoid the risk of possible double count-
ing with participants from another related study [29].
This study found that the risk of liver-related mortality
was significantly lower in cART patients with com-
pensated cirrhosis compared to untreated patients
(unadjusted HR 0.5; 95 % CI 0.3 to 0.9). Adding the results
of this study to the meta-analysis had a limited effect on
the overall findings (RR 0.46, 95 % CI 0.28 to 0.75).
Liver disease outcomes
Liver disease outcomes were reported too diversely, or
in too few studies for meta-analysis and we synthesised
the findings narratively [24, 25, 27–30, 32, 33, 35, 36]. A
summary of the findings from these studies is presented
in Table 3.
End-stage liver disease and decompensation events
Three studies reported data on end-stage liver disease or
liver decompensation events [27, 29, 32]. Two of these
studies found at least one statistically significant effect in
favour of cART [27, 29].
Table 2 Intervention and patient characteristics
Study Country Start-end date Total N (I/C)a % with prior
HCV therapy
% with concomitant
HCV therapy
Age (years) Male % Baseline liver damage (%) Current or past substance abuse (%)
Bruno (2007) [34] Italy 1999-2004 53 (29/24) NR NR median 37.1 90 100 compensated cirrhosis NR
Giron-Gonzalez (2007) [29] Spain 2004-2006 92 (76/22) 19 8 median 40 89 100 compensated cirrhosis Alcohol: 46 current
IDU: 90
Limketkai (2012) [23] USA 1993-2011 638 (440/198) NR NR median 45.6 66 METAVIR F0-F2: 82
F3: 6
F4: 1
Alcohol: 47 current
IDU: 76 past
Macias (2009) [24] Spain 1986-2008 135 (113/22) NR 44 mean 37 68 Scheuer
F0-F2: 78
F3: 22
F4: 0
Alcohol: 21 current
IDU: 90
Macias (2006) [25] Spain 1991-2005 683 (509/174) NR 0 median 23c 83 Scheuer
F0-F2: 68
F3: 18
F4: 14
Alcohol: 23 current
IDU: 86 current
Mariné-Barjoan (2004) [35] France 1997-2000 116 (91/25) 0 0 median 21c 67 METAVIR F0-F2: 74
F3-4: 26
Alcohol: 14 current
IDU: 72
Mehta (2005) [30] USA 2001-NRb 210 (135/75) 0 NR median 44.5 67 Ishak
F0-F2: 74
≥F3:26
Alcohol: 39.5 history
IDU: 77 current or past
Merchante (2006) [31] Spain 1997-2004 153 (101/58) 6 NR median 38 86 100 compensated cirrhosis Alcohol: 46 current
IDU: 88 previous
Pineda (2009) [32] Spain 1996-2006 154 (145/9) NR 43 median 39.9 87 100 compensated cirrhosis Alcohol: 21
IDU: 86 current or previous
Qurishi (2003) [26] Germany 1990-2002 285 (148/137) NR 0 median 30 95 No symptomatic liver disease Alcohol: 12
IDU: 15
Ragni (2009) [27] USA 1970-2005 85 (60/25) NR 1 mean 39d 100 No cirrhosis Alcohol: 12
IDU: NR
Reiberger (2010) [36] Austria NR-NR 74 (49/25) 0 0 mean 37 77 METAVIR F0-F2: 59
F3-F4: 41
Alcohol: 29 current
IDU: NR
Sanmartin (2014) [33] Spain 1997-2010 162 (149/13) 0 54 mean 37 73 Scheuer
F0-F2: 100
Alcohol & IDU: 0 current
Schiavini (2006) [28] Italy 1985-2002 36 (20/16) NR 92 median 28 75 Ishak-Knodell
F0-2: 75
F3-4: 25
Alcohol: 53 history
IDU: NR
ART: 0.279 (0 · 122–0 · 414); untreated: 0.255 (0 · 079–0 · 473); untreated: 145 (SD 43, range 2–610) (time of measurement UC)
aI = Intervention, C = Control
bMedian follow-up 5 years (IQR 2.9-7.5)
cAt HCV infection
dAt follow-up
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Fig. 2 Adjusted odds or hazard of liver-related mortality in HIV/HCV co-infected patients receiving cART versus no cART. Variables adjusted for:
Giron-Gonzalez (2007): HCV viral load, liver disease severity, liver disease progression, decompensation during or before follow-up. Limketkai
(2012): Age, sex, race, injection drug use, time-varying CD4 cell count and current cART exposure. Pineda (2009): Not reported. Qurishi (2003): Sex,
age, risk category, alcohol misuse, HBV, CD4 count, AAT, AST, cholinesterase bilirubin, platelets count, immunoglobulin concentration
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haemophilia receiving cART and/or ARV monotherapy and
untreated patients in the risk of developing end-stage liver
disease over 35 years (RR 1.00; 95 % CI 0.37 to 2.71). How-
ever, patients receiving cART survived longer before pro-
gressing to end-stage liver disease compared with untreated
patients (30.3 vs. 20.0 years; HR 3.14; 95 % CI 1.27 to 7.08).
Two studies reported on the risk of liver decompensa-
tion in patients with liver cirrhosis [29, 32]. One [29]Fig. 3 Unadjusted relative risk of liver-related mortality in HIV/HCV co-infecfound a significantly lower risk of a new event of decom-
pensation in cART patients with stable cirrhosis who
had experienced decompensation in the past (HR 0.376;
95 % CI 0.161 to 0.883). However, no statistically signifi-
cant difference was found in the subgroup of patients
with no previous decompensation at baseline. Similarly,
the other [32] found no significant difference between
cART and untreated patients in the risk of decompensa-
tion in individuals with cirrhosis.ted patients receiving cART versus no cART
Fig. 4 Unadjusted relative risk for liver-related mortality in HIV/HCV co-infected haemophiliac patients receiving cART versus no cART
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Seven studies reported on liver damage in patients with
no cirrhosis at baseline, expressed in terms of odds/
hazard of fibrosis progression, [24, 25, 28, 30, 33]
and/or progression rate [25, 35, 36]. Of the five studies
that reported the odds/hazard of fibrosis progression, only
one reported a statistically significant difference between
intervention and control. This study [25] found signifi-
cantly lower odds of liver fibrosis progression in patients
on cART with protease inhibitors (PI) (OR 0.4; 95 % CI
0.2 to 0.7) and in patients who switched from a PI
based regimen to efavirenz during the course of their
treatment (OR 0.3; 95 % CI 0.1 to 0.7), but not with
other regimens.
Of the three studies that reported fibrosis progression
rates, two found a difference in favour of cART [25, 35],
and one found no difference between cART and no
treatment [36]. One [25] found slower median rates of
fibrosis progression in patients treated with cART com-
pared with untreated patients, regardless of regimens
used. However, the difference was only statistically sig-
nificant for some regimens (zidovudine/lamivudine and
stavudine/lamivudine). Another [35] found a slower mean
rate of fibrosis progression over approximately 15 years in
patients undertaking cART at follow-up, although the dif-
ference did not reach statistical significance.
Discussion
We included 14 studies evaluating the association be-
tween cART and/or ARV monotherapy and liver disease
progression and liver-related mortality in patients co-
infected with HIV and hepatitis C. In most studies the
majority of patients had a history of IDU, except for two
studies that included only or mostly participants with
haemophilia. cART was found to be associated with asubstantial reduction in liver-related mortality, with a
chance/hazard around one-third of that in untreated pa-
tients. Pooled estimates from unadjusted analyses also
showed a clear association in favour of cART for pre-
venting liver-related mortality. A subgroup analysis in-
cluding nearly all patients with haemophilia also found a
reduced incidence of liver related mortality in individ-
uals receiving cART, but there were too little data to
provide an accurate estimate or to determine if the effect
differed from other populations. Findings for other liver-
related outcomes were less consistent, although no
studies reported that lack of cART or ARV monother-
apy was associated with significantly better liver-disease
outcomes.
Strengths and limitations
This systematic review was conducted following the gen-
eral principles recommended in CRD Guidance for
Undertaking Reviews in Health Care, and the reporting
guidance of the PRISMA and MOOSE statements [15, 16].
Study quality was assessed systematically and considered
when interpreting the findings. Whenever possible, data
on treatment effect for individual studies were extracted
or calculated, even when quantitative synthesis was not
undertaken. The review was completed within a ten-week
timeframe to meet the needs of the Department of Health
in England and due to time constraints we did not search
for conference abstracts, included only English language
studies and one reviewer screened titles and abstracts.
This means that relevant studies may have been missed,
and the risk of publication bias cannot be ruled out.
Quantitative assessment of publication bias was consid-
ered inappropriate due to the limited number of included
studies. Despite the limitations of our searches, we believe
it is unlikely that any potential missed studies would
Table 3 Liver fibrosis progression, decompensation and end stage liver disease outcomes
Study Intervention Outcome Follow-up duration Effect estimate Statistically
significant?a
Adjustments
End-stage liver disease (ESLD) and decompensation events
Giron-Gonzalez (2007) [29] cART Decompensationj Median 20 months (IQR 12 to 28) HR 0.376 (95 % CI 0.161 to 0.883) Yes. Favours
treatment
Liver disease
severity
Giron-Gonzalez (2007) [29] cART Decompensationj Median 20 months (IQR 12 to 28) NR No None
Pineda (2009) [32] cART Decompensation Mean 36 months (SD 27),
range 1 to 131 months
RR 1.06 (95 % CI 0.30 to 3.71) No None
Ragni (2009) [27] cART & ARV monotherapy ESLD NR (up to 35 years from HCV infection) RR 1.00 (95 % CI 0.37 to 2.71) No None
Ragni (2009) [27] cART vs. ARV monotherapy & no ARVb Time to ESLD NR (up to 35 years from HCV infection) HR 3.14 (95 % CI 1.27 to 7.08)
(30.3 vs. 20.0 Years)
Yes. Favours
treatment
Multivariate
(covariates NR)
Liver fibrosis progression (dichotomous)
Macias (2006) [25] cART with PI Liver fibrosis progressiond Median 1.6 to 7 years OR 0.4 (95 % CI 0.2 to 0.7) Yes. Favours
treatment
Age at infection,
CD4 count
Macias (2006) [25] cART with PI switched to efavirenz Liver fibrosis progressiond Median 1.6 to 7 years OR 0.3 (95 % CI 0.1 to 0.7) Yes. Favours
treatment
Age at infection,
CD4 count
Schiavini (2006) [28] cART and ARV monotherapy Liver fibrosis progressione Median 54 months (IQR 50 to 86) OR 2.5 (95 % CI 0.64 to 9.65) No None
Macias (2009) [24] cART and ARV monotherapy Liver fibrosis progressionh 3 years OR 0.94 (95 % CI 0.67 to 1.33) No Multivariatek
Mehta (2005) [30] ARV monotherapy Advanced fibrosis or cirrhosisc Median 5 years (IQR 2.9 to 7.5) OR 0.61 (95 % CI 0.18 to 2) No None
Mehta (2005) [30] cART Advanced fibrosis or cirrhosisc Median 5 years (IQR 2.9 to 7.5) OR 0.92 (95 % CI 0.48 to 1.8) No None
Sanmartin (2014) [33] cART Liver fibrosis progressioni Median 7.8 years (IQR 5.5 to 10.0) HR 1.94 (95 % CI 0.46 to 8.13) No None
Liver fibrosis progression (continuous)
Macias (2006) [25] cART with: NVP; or efavirenz;
or with PI switched to NVP
Fibrosis progression ratef Median 1.6 to 7 years Median rate 0.087 to 0.115 No None
Macias (2006) [25] cART with zidovudine/lamivudine,
or with stavudine/lamivudine
Fibrosis progression ratef Median 1.6 to 7 years Median rate 0.107 and 0.112 Yes. Favours
treatment
None
Mariné-Barjoan (2004) [35] cART Fibrosis progression ratef Median 19 to 20 years MD −0.06 (95 % CI −0.14 to 0.01) No None
Reiberger (2010) [36] cART Fibrosis progression ratef NR MD 0.01 (95 % CI −0.01 to 0.04) No None
Reiberger (2010) [36] cART Time to cirrhosisg from initial
HCV exposure
NR MD −1.00 (95 % CI −7.26 to 5.26) No None
cART combination antiretroviral therapy, PI protease inhibitors, NVP nevirapine
ap < 0.05
bARV monotherapy patients formed 62 % of the comparator group in this analysis
cIshak score ≥ F3 measured with liver biopsy
dOdds of slower fibrosis proression (fibrosis progression rate ≥0.2 vs <0.2), fibrosis measured with liver biopsy
e≥1 Knodell-Ishak stage increase between two liver biopsies
fMETAVIR Fibrosis stage (0 to 3) measured by liver biopsy/length of HCV infection
gIn years, measured with liver biopsy
h≥1 Scheuer stage increase between two liver biopsies spaced by ≥1 year
iLiver stiffness value ≥9.5 kPa or died of liver disease
jSubgroup without previous decompensation at baseline
kAge, undetectable HIV viraemia, genotype 3, ALT and necroinflammatory activity at baseline, time between liver biopsies, HCV treatment response
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liver-related mortality and our main conclusions. This is
because the observed effect associated with cART is
substantial.
Findings from most studies on liver-related mortality
were synthesised quantitatively. Adjusted and unadjusted
results were pooled separately as an attempt to address
potential confounding. Adjusted mortality values could
only be combined based on the (inaccurate) assumption
that odds and hazard ratios are equivalent, and this ap-
proach could create heterogeneity across studies because
of different analysis methods used to obtain the adjusted
results; therefore these results need to be interpreted
with caution. However, the pooled estimates from ad-
justed and unadjusted values did not differ significantly,
and both suggested substantial benefits of cART.
Liver disease outcomes were reported too diversely, or
in too few studies for statistical pooling. This limits the
strength of the findings on liver disease progression.
There were too few studies to conduct meta-regression
or further subgroup analyses to explore the moderating
effect of several relevant factors, including age, liver dis-
ease severity, baseline CD4 count, HBV co-infection, co-
intervention with HCV therapy, time since HCV/HIV
infection, HIV treatment duration treatment history of
HCV infection or alcohol abuse.
Unsurprisingly, no RCTs were identified and all in-
cluded studies were observational. Given the known
overall survival benefits associated with cART, it would
be unethical to randomise patients to no cART. Half of
the studies adjusted for potential confounders such as
age or sex, although the variables accounted for varied
across the studies. For instance, only two studies con-
trolled for alcohol misuse in their analyses. Although at-
tempts were made to address the risk of confounding in
the analyses, risk of confounding cannot be ruled out.
The pooled analyses showed heterogeneity, particularly
for the meta-analysis of adjusted results, which limits
the strength of the review findings.
Studies might have been affected by a survivorship
bias if patients in the intervention group who survived
long enough to receive treatment had slower HCV
progression, and therefore may have had better HCV-
related outcomes [13]. The use of a time-dependent vari-
able or Cox proportional hazards modelling taking HCV
duration or progression into account might have remed-
ied this bias. However, no studies reported using this
technique. On the other hand, it is possible that com-
parison groups had levels of immunosuppression that
were considered sufficiently high for their treatment
to be delayed [37–39]. In this case, patients in the
ART group may have had poorer health at treatment
initiation, and may therefore have been at higher risk
of liver disease progression. Unfortunately, reportingof participant characteristics in the studies was insuf-
ficient to support or reject these assumptions.
Reasons for not receiving cART or ARV monotherapy
were generally not reported. However, given that cART,
and previously ARV monotherapy, would likely be rec-
ommended to most HIV/HCV co-infected individuals,
particularly those with high HIV viral load, reasons for
not receiving treatment were likely influenced by indi-
vidual patient choice. Those receiving cART may be less
likely to be active IDUs (for example, ex-IDUs on
methadone programmes) and may have different life-
styles (for example, less alcohol and substance abuse)
compared to those who do not receive cART. Reporting
of baseline differences between cART/ARV monotherapy
and untreated groups was often limited. Although no
studies reported significant differences between groups
such as current alcohol, IDU or other substance abuse,
and although some studies adjusted for these variables in
their analyses, it is still possible that those who received
treatment for HIV were different to those who did not for
reasons that may have influenced liver-related outcomes.
Where reported, most participants had a history of
IDU. This should be taken into account when interpret-
ing the results of the review. Most participants included
in the studies were under 50 years of age and the burden
of other co-morbidities is likely to be higher in older
populations. This, in addition to the toxicity of other
treatments, may impact differently upon liver disease.
This limits the applicability of the findings to older pop-
ulations, especially given the increasing life expectancy
of people with HIV and HCV, and the growing propor-
tion of people with HIV aged 50 years and over.
We identified only studies from high-income countries
and note that the applicability of the review findings to
low- and middle-income countries is uncertain.
Implications for policy, practice and further research
This systematic review provides an up-to-date synthesis
of the available evidence on the effect of cART and ARV
monotherapy on liver disease progression and liver-
related mortality in individuals co-infected with HIV and
hepatitis C. This review, together with another review
on quality of life and extrahepatic conditions in individ-
uals with chronic hepatitis C, [40] was commissioned as
part of ongoing policy consideration about the shape of
support for those affected by hepatitis C or HIV from
historic NHS blood treatments before donor screening
tests or virus inactivation methods were available in the
UK. A public consultation on reform of the existing fi-
nancial and other support available was announced in
January 2016.
The findings of this review support the use of cART in
patients co-infected with HIV and HCV as recommended
by current guidelines [39, 41]. Given the increased risk of
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infected with HIV and HCV and the limited evidence on
the impact of cART on liver disease progression, the need
for monitoring liver-disease progression in this population
clearly remains. Future management of patients co-
infected with HIV and HCV is likely to evolve with the ad-
vent of new directly acting antivirals (DAAs) for the treat-
ment of HCV, [42–45] and recent trials have found high
sustained virologic response (SVR) rates in non-cirrhotic
patients co-infected with HIV and HCV with certain DAA
combinations [46, 47].
Few included studies reported data separately for dif-
ferent antiretroviral classes and combinations. Several
studies comparing different ARV regimens did not com-
pare cART and/or ARV monotherapy with no HIV treat-
ment and were therefore excluded from our review.
Given the ubiquitous use of cART in HIV management,
a systematic review on the acute and chronic effect of
different cART regimens would be relevant. The mecha-
nisms by which liver disease mortality is reduced with
cART are still largely unknown [27]. Further research
would clarify whether the effect of cART on liver-disease
progression and mortality may occur through immune
reconstitution, viral suppression or a combination of
both [13].
Conclusions
The use of cART was found to be associated with a signifi-
cantly reduced risk of liver-related mortality in patients
co-infected with HIV and HCV. Evidence of a positive as-
sociation with liver disease progression is less clear, al-
though there is no evidence to suggest that the absence of
cART and/or ARV monotherapy is preferable.
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